SPRC SEC-Einreichungen - SciSparc Ltd.- Jahresbericht, Proxy Statement, Prospekt

Basisstatistiken

CIK

1611746

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to SciSparc Ltd.

SEC Filings (Chronological Order)

Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.

June 4, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2026 Commission File Number: 001-38041 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2026 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal execu
June 4, 2026	EX-99.1	SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum Exhibit 99.1 SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the clo
May 29, 2026	EX-99.1	SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum Exhibit 99.1 SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum TEL AVIV, Israel, May 28, 2026 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous s
May 29, 2026	EX-10.1	AMENDING AGREEMENT Exhibit 10.1 AMENDING AGREEMENT THIS AGREEMENT made as of the 30th day of April, 2026. AMONG: SHAREHOLDERS OF CLINIQUANTUM LTD. as set out in Section 3.03 of the Disclosure Schedules (as defined in the SPA (as defined below)) (hereinafter referred to as the “Selling Shareholders”) OF THE FIRST PART -and- CLINIQUANTUM LTD. a corporation incorporated under the laws of the State of Israel (hereinafte
May 29, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2026 (Report No. 2) Commission File Num UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2026 (Report No. 2) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of p
May 11, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2026 Commission File Number: 001-38041 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2026 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal execut
April 29, 2026	EX-2.1	DESCRIPTION OF SHARE CAPITAL Exhibit 2.1 DESCRIPTION OF SHARE CAPITAL The following description of SciSparc Ltd.’s (the “Company”) share capital and provisions of the amended and restated articles of association (the “Articles”) are summaries and do not purport to be complete. Registration number and purposes of the Company Our registration number with the Israeli Registrar of Companies is 51-358165-2. Our purpose as set fort
April 29, 2026	EX-13.1	CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2025 (the “Report”) by SpiSparc Ltd. (the “Company”), the undersigned, as the Chief Executive Officer and Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report ful
April 29, 2026	EX-4.29	SHARE PURCHASE AGREEMENT SHAREHOLDERS OF CLINIQUANTUM LTD., AS SELLING SHAREHOLDERS CLINIQUANTUM LTD., AS THE COMPANY NEUROTHERA LABS INC., AS THE PURCHASER dated as of March 9, 2026 SHARE PURCHASE AGREEMENT Exhibit 4.29 SHARE PURCHASE AGREEMENT between SHAREHOLDERS OF CLINIQUANTUM LTD., AS SELLING SHAREHOLDERS and CLINIQUANTUM LTD., AS THE COMPANY and NEUROTHERA LABS INC., AS THE PURCHASER dated as of March 9, 2026 SHARE PURCHASE AGREEMENT THIS AGREEMENT is made as of the 9th day of March, 2026. BETWEEN: SHAREHOLDERS OF CLINIQUANTUM LTD. as set out in Section 3.03 of the Disclosure Schedules (hereina
April 29, 2026	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.
April 29, 2026	EX-15.2	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statements on Form S-8 (File Nos. 333-225773, 333-278437, 333-286791 and 333-292952) and Registration Statements on Form F-3 (File Nos. 333-255408, 333-266047, 333-275305, 333-293167 and 333-293533) of our report dated April 29, 2026, relating to the consolidated finan
April 29, 2026	EX-11.1	SCISPARC LTD. INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN COMPANY SECURITIES Amended on: April 29, 2026 Exhibit 11.1 SCISPARC LTD. INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN COMPANY SECURITIES Amended on: April 29, 2026 This Insider Trading Policy (the “Policy”) provides guidelines to directors, officers, employees and other related individuals of SciSparc Ltd., an Israeli company (the “Company”), with respect to transactions in the Company’s securities. The Compan
April 29, 2026	EX-12.1	CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a) I, Oz Adler, certify that: 1. I have reviewed this annual report on Form 20–F of SciSparc Ltd. (the “Company”); 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances unde
April 29, 2026	EX-15.1	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statements (Form F-3 Nos. 333-275305, 333-266047, 333-255408, 333-293167, and 333-293533) of SciSparc Ltd., and (2) Registration Statements (Form S-8 Nos. 333-225773, 333-278437, 333-286791, and 333-292952) pertaining to the T
March 16, 2026	EX-99.1	SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy Exhibit 99.1 SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervou
March 16, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2026 (Report No. 3) Commission File N UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2026 (Report No. 3) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of
March 12, 2026	EX-99.2	SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease Exhibit 99.2 SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease TEL AVIV, Israel, March 12, 2026 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical
March 12, 2026	EX-99.1	SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails Exhibit 99.1 SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails TEL AVIV, Israel, March 10, 2026 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on d
March 12, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2026 (Report No. 2) Commission File N UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2026 (Report No. 2) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of
March 2, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2026 Commission file number: 001-3804 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2026 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal exec
March 2, 2026	EX-99.1	SciSparc Announces 1-for-9 Reverse Share Split Following the reverse share split, the Company will have approximately 565,000 outstanding shares, out of which approximately 561,533 will be publicly held Exhibit 99.1 SciSparc Announces 1-for-9 Reverse Share Split Following the reverse share split, the Company will have approximately 565,000 outstanding shares, out of which approximately 561,533 will be publicly held Tel Aviv, Israel, March 2, 2026 (GLOBE NEWSWIRE) - SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a company engaged in clinical-stage pharmaceutical developments through i
February 17, 2026	EX-10.1	SIDE LETTER TO SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SIDE LETTER TO SECURITIES PURCHASE AGREEMENT This Side Letter (this “Side Letter”) dated as of February 12, 2026, is entered into by and between SciSparc Ltd., a company incorporated under the laws of the State of Israel (the “Company”), and L.I.A. Pure Capital Ltd. (the “Buyer”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the S
February 17, 2026	F-3	As filed with the Securities and Exchange Commission on February 17, 2026 As filed with the Securities and Exchange Commission on February 17, 2026 Registration No.
February 17, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2026 (Report No. 4) Commission fi UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2026 (Report No. 4) Commission file number: 001- 38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Addre
February 17, 2026	EX-FILING FEES	CALCULATION OF FILING FEE TABLES SciSparc Ltd. Table 1: Newly Registered and Carry Forward Securities Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-3 SciSparc Ltd. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary shares, no par
February 12, 2026	EX-4.2	ORDINARY SHARES PURCHASE WARRANT SCISPARC LTD. Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T
February 12, 2026	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of February 12, 2026, is between SciSparc Ltd. a company incorporated under the laws of the State of Israel, with principal executive offices located at 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 , Israel (the “Company”), and L.I.A. Pure Capital Ltd. (the “Buyer”). WITNESSETH WHEREA
February 12, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2026 (Report No. 3) Commission fi UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2026 (Report No. 3) Commission file number: 001- 38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Addre
February 12, 2026	EX-4.1	SCISPARC LTD Convertible Promissory Note Exhibit 4.1 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD
February 10, 2026	CORRESP	SciSparc Ltd. 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel SciSparc Ltd. 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel February 10, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: SciSparc Ltd. (CIK: 0001611746) Registration Statement No. 333-293167 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: SciSparc Ltd. (the “Registrant”) her
February 9, 2026	LETTER	LETTER February 9, 2026 Oz Adler Chief Executive Officer SciSparc Ltd. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel Re: SciSparc Ltd. Registration Statement on Form F-3 Filed February 3, 2026 File No. 333-293167 Dear Oz Adler: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration
February 4, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2026 (Report No. 2) Commission fil UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2026 (Report No. 2) Commission file number: 001- 38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Addres
February 3, 2026	EX-FILING FEES	CALCULATION OF FILING FEE TABLES SCISPARC LTD. Table 1: Newly Registered and Carry Forward Securities Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-3 SCISPARC LTD. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary Shares, no par
February 3, 2026	F-3	As filed with the Securities and Exchange Commission on February 3, 2026 As filed with the Securities and Exchange Commission on February 3, 2026 Registration No.
February 2, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2026 Commission file number: 001- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2026 Commission file number: 001- 38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal
February 2, 2026	EX-99.1	SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA Exhibit 99.1 SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA NeuroThera’s Proprietary Cannabinoid-Enhanced Platform Targets Antibiotic Resistance Using Approved Antimicrobials TEL AVIV, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc.
January 26, 2026	EX-4.1	PREFUNDED ORDINARY SHARE PURCHASE WARRANT SCISPARC LTD. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG
January 26, 2026	EX-99.1	SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization SciSparc intends to target the global multi- billion dollar GERD device market Exhibit 99.1 SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization SciSparc intends to target the global multi- billion dollar GERD device market TEL AVIV, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsi
January 26, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2026 (Report No. 4) Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2026 (Report No. 4) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
January 26, 2026	S-8	As filed with the Securities and Exchange Commission on January 26, 2026 As filed with the Securities and Exchange Commission on January 26, 2026 Registration No.
January 26, 2026	EX-FILING FEES	CALCULATION OF FILING FEE TABLES SciSparc Ltd. Table 1: Newly Registered Securities Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 SciSparc Ltd. Table 1: Newly Registered Securities Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, no par value per share (1) Other 984,810 $ 0.9850 $ 970,037.85 0.0001381 $ 133.96 T
January 14, 2026	424B5	766,170 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-269839 Prospectus Supplement (To Prospectus dated February 23, 2023) 766,170 Ordinary Shares We are offering directly to certain institutional and accredited investors, or the Investors, in a registered direct offering, or the Offering, 766,170 of our ordinary shares, no par value per share, or the Ordinary Shares, through this prospectus suppl
January 13, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2026 (Report No. 2) Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2026 (Report No. 2) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
January 13, 2026	EX-10.1	ASSET PURCHASE AGREEMENT Exhibit 10.1 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (the “Agreement”), is made effective as of January 8, 2026 (the “APA Effective Date”), by and between: XYLO Technologies Ltd., a private company organized under the laws of the State of Israel, company registration number 512866971, registered address at 10 Hanechoshet St., Tel Aviv – Yafo 6971072, Israel (the “Seller”); and SciSp
January 13, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2026 (Report No. 3) Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2026 (Report No. 3) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
January 13, 2026	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 13, 2026, between SciSparc Ltd., an Israeli corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set for
January 13, 2026	EX-99.1	SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity SciSparc intends to commence commercialization of these patented technologies immediately following the transacti Exhibit 99.1 SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity SciSparc intends to commence commercialization of these patented technologies immediately following the transaction closing TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged i
January 12, 2026	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2026 Commission File Number: 001-38 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2026 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal ex
January 12, 2026	EX-99.1	SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance Exhibit 99.1 SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today that it has received a written notification
December 31, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of: December 2025 (Report No. 2) Commission fi UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of: December 2025 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916, Israel (Addres
December 31, 2025	EX-16.1	December 31, 2025 Exhibit 16.1 December 31, 2025 Securities and Exchange Commission 100 F Street NE Washington, D.C. 20549 We have read the statements under the heading “Change in Registrant’s Certifying Accountant” included in the Report of Foreign Private Issuer on Form 6-K of SciSparc Ltd. dated December 31, 2025, and are in agreement with the statements contained in the third and fourth paragraphs therein. We h
December 31, 2025	EX-99.1	Notice of Special General Meeting of Shareholders To be Held on February 4, 2026 Exhibit 99.1 December 31, 2025 Dear SciSparc Ltd. Shareholders: We cordially invite you to attend the Special General Meeting of Shareholders of SciSparc Ltd. (the “Meeting”), to be held on Wednesday, February 4, 2026 at 3:00 p.m. (Israel time), at the Company’s offices, at 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel. At the Meeting, shareholders will be asked to consider and vote o
December 31, 2025	EX-99.2	SCISPARC LTD. (THE “COMPANY”) Special General Meeting of Shareholders To be held February 4, 2026 This proxy is solicited by the Board of Directors Exhibit 99.2 SCISPARC LTD. (THE “COMPANY”) Special General Meeting of Shareholders To be held February 4, 2026 This proxy is solicited by the Board of Directors The undersigned shareholder(s) hereby appoint(s) Oz Adler, the Company’s Chief Executive Officer and Chief Financial Officer, and Itschak Shrem, the Chairman of the Board of Directors of the Company, and each of them, as proxies and attorn
December 23, 2025	POS AM	As filed with the Securities and Exchange Commission on December 23, 2025 As filed with the Securities and Exchange Commission on December 23, 2025 Registration No.
December 23, 2025	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction Ownership Interest Brain Bright Ltd. Israel 100% Evero Health Ltd. Israel 100% Neurothera Labs Inc. Canada 75% Scisparc Merger Sub Ltd. Israel 100%
December 2, 2025	EX-99.1	SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company Exhibit 99.1 SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments
December 2, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2025 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2025 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal e
November 28, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2025 (Report No. 4) Commission Fil UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2025 (Report No. 4) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
November 28, 2025	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 27, 2025, between SciSparc Ltd., an Israeli corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fo
November 28, 2025	424B5	1,292,557 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-269839 Prospectus Supplement (To Prospectus dated February 23, 2023) 1,292,557 Ordinary Shares We are offering directly to certain institutional and accredited investors, or the Investors, in a registered direct offering, or the Offering, 1,292,557 of our ordinary shares, no par value per share, or the Ordinary Shares, through this prospectus s
November 26, 2025	EX-10.1	BINDING TERM SHEET FOR THE SALE OF PATENT PORTFOLIO & TRADEMARKS Exhibit 10.1 Confidential BINDING TERM SHEET FOR THE SALE OF PATENT PORTFOLIO & TRADEMARKS This Term Sheet is made and entered into this 26 day of November 2025, by and between the undersigned parties. The intent of this Term Sheet is to describe the principal terms and conditions according to which Buyer will enter into a definitive agreement with the Seller (the “Definitive Agreement”). 1. Selle
November 26, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2025 (Report No. 3) Commission Fil UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2025 (Report No. 3) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
November 26, 2025	EX-99.1	SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems Exhibit 99.1 SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems TEL AVIV, Israel, Nov. 26, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., today announced the signing of a binding term sheet to acquire a treasury o
November 20, 2025	EX-99.1	SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression Exhibit 99.1 SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression TEL AVIV, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical comp
November 20, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2025 (Report No. 2) Commission Fil UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2025 (Report No. 2) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
November 18, 2025	EX-99.2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjuncti
November 18, 2025	EX-99.1	SCISPARC LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 Exhibit 99.1 SCISPARC LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 UNAUDITED INDEX Page Consolidated Statements of Financial Position 2-3 Consolidated Statements of Profit or Loss and Other Comprehensive Loss 4 Consolidated Statements of Changes in Equity (Deficit) 5-7 Consolidated Statements of Cash Flows 8-10 Notes to Interim Consolidated Financial Statements 11-27 1 SCISPA
November 18, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2025 Commission file number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2025 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal e
November 4, 2025	424B3	SCISPARC LTD. Filed pursuant to Rule 424(b)(3) Registration No. 333-282351 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated July 21, 2025) SCISPARC LTD. This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-4(Registration No. 333-282351), effective as of July 21, 2025 (as supplemented or amended from time to time, the “Prospectus”). Capitaliz
November 4, 2025	RW	November 4, 2025 November 4, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
October 27, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2025 (Report No. 5) Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2025 (Report No. 5) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
October 27, 2025	EX-99.1	1 Exhibit 99.1 SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio TEL AVIV, Israel, Oct. 24, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and ra
October 24, 2025	EX-99.1	SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer Exhibit 99.1 SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapie
October 24, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2025 (Report No. 4) Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2025 (Report No. 4) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
October 20, 2025	EX-99.1	SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders Exhibit 99.1 SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders TEL AVIV, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, annou
October 20, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2025 (Report No. 3) Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2025 (Report No. 3) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
October 15, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2025 (Report No. 2) Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2025 (Report No. 2) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
October 15, 2025	EX-99.2	According to the agreement, SciSparc’s pharmaceuticals assets and equity stake in SciSparc Nutraceuticals Inc. are valued at approximately US$11.6 million Exhibit 99.2 SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio According to the agreement, SciSparc’s pharmaceuticals assets and equity stake in SciSparc Nutraceuticals Inc. are valued at approximately US$11.6 million TEL AVIV, Israel, Oct. 15, 2025 (GLOBE NEWSWIRE) -
October 15, 2025	EX-99.1	MIZA III VENTURES INC. SCISPARC LTD. Exhibit 99.1 MIZA III VENTURES INC. and SCISPARC LTD. ASSET AND SHARE PURCHASE AGREEMENT OCTOBER 9, 2025 TABLE OF CONTENTS Part 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Schedules 9 1.3 Interpretation 9 1.4 Governing Law 10 1.5 Severability 10 1.6 Entire Agreement 10 1.7 Waiver 10 Part 2 Purchase and Sale AND RELATED TRANSACTIONS 10 2.1 Purchase 10 2.2 Retention of Liabilities 11 2.3 Consideration
October 6, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2025 Commission File Number: 001-38 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2025 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal ex
October 6, 2025	EX-99.1	FRAMEWORK AGREEMENT Exhibit 99.1 FRAMEWORK AGREEMENT This Framework Agreement (the “Agreement”) is dated as of October 6, 2025 (the “Effective Date”), by and between AutoMax Motors Ltd. (the “Borrower”), SciSparc Ltd. (“Lender”) and SciSparc Merger Sub Ltd. (“Merger Sub”) (the Borrower, Lender and Merger Sub collectively, the “Parties” and individual a “Party”). R E C I T A L S WHEREAS, on April 10, 2024, the Parties
October 6, 2025	EX-99.2	SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors Exhibit 99.2 SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors TEL AVIV, Israel, Oct. 06, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the entry into a framework agreement f
September 30, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 (Report No. 5) Commission Fi UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 (Report No. 5) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Addres
September 30, 2025	EX-99.1	SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer Exhibit 99.1 SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer TEL AVIV, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the develop
September 26, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 (Report No. 4) Commission Fi UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 (Report No. 4) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Addres
September 26, 2025	EX-10.1	ScISPARC LTD. Exhibit 10.1 ScISPARC LTD. September 26, 2025 Holder of Warrants to Purchase Ordinary Shares Issued in February 2025 Re: Inducement Offer to Exercise Warrant to Purchase Ordinary Shares Issued in February 2025 Dear Holder: SCISPARC LTD. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive a reduction in the Exercise Price of certain warrant
September 25, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2025 (Report No. 3) Commission f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2025 (Report No. 3) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916, Israel (Addre
September 25, 2025	EX-99.1	SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery Exhibit 99.1 SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, tod
September 16, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 (Report No. 2) Commission Fi UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 (Report No. 2) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Addres
September 8, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number: 001- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal
August 29, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 (Report No. 5) Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 (Report No. 5) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address o
August 28, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 (Report No. 4) Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 (Report No. 4) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address o
August 28, 2025	EX-99.2	SciSparc: AutoMax’s Shareholders Approve Merger with SciSparc Exhibit 99.2 SciSparc: AutoMax’s Shareholders Approve Merger with SciSparc TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that AutoMax Motors Ltd. (“AutoMax”), a leading parallel
August 28, 2025	EX-99.1	SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel Exhibit 99.1 SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that at adjourned special gener
August 26, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 (Report No. 3) Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 (Report No. 3) Commission file number: 001- 38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
August 25, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August (Report No. 2) Commission file numb UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August (Report No. 2) Commission file number: 001- 38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of p
August 8, 2025	EX-99.1	SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar Exhibit 99.1 SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar TEL AVIV, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare di
August 8, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number: 001-380 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal exe
July 31, 2025	EX-99.1	SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease Exhibit 99.1 SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare
July 31, 2025	EX-99.2	SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC Exhibit 99.2 SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announces addi
July 31, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 (Report No. 3) Commission File Nu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 (Report No. 3) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of
July 28, 2025	CORRESP	SciSparc Ltd. 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel SciSparc Ltd. 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel July 28, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: SciSparc Ltd. (CIK 0001611746) Registration Statement No. 333-286099 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: SciSparc Ltd. (the “Registrant”) hereby requests acceler
July 22, 2025	EX-99.2	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 99.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: 1. Registration Statements (Form F-3 Nos. 333-275305, 333-269839, 333-266047, 333-248670, and 333-255408) of SciSparc Ltd., and 2. Registration Statements (Form S-8 Nos. 333-278437, 333-225773, and 333-286791) pertaining to the Therapix Biosci
July 22, 2025	EX-99.1	SCISPARC LTD. AND ITS SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2024 U.S. DOLLARS IN THOUSANDS Exhibit 99.1 SCISPARC LTD. AND ITS SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2024 U.S. DOLLARS IN THOUSANDS INDEX Page Report of Independent Registered Public Accounting Firm (PCAOB ID 1281) F-2 - F-3 Consolidated Statements of Financial Position F-4 - F-5 Consolidated Statements of Comprehensive Loss F-6 Consolidated Statements of Changes in Equity F-7 Consolidated Stateme
July 22, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-38041 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal execu
July 22, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 (Report No. 2) Commission file nu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of
July 22, 2025	F-3/A	As filed with the Securities and Exchange Commission on July 22, 2025 As filed with the Securities and Exchange Commission on July 22, 2025 Registration No.
July 22, 2025	EX-99.1	SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification Exhibit 99.1 SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification Tel Aviv, July 22, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, reported the receipt on July 18, 2025 of a writte
July 21, 2025	424B3	PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT Filed Pursuant to Rule 424(b)(3) Registration No. 333-282351 PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Shareholders of SciSparc Ltd.: You are cordially invited to attend a special meeting of the shareholders of SciSparc Ltd., or SciSparc, an Israeli limited company, which we refer to as “we,” “SciSparc,” or the “Company,” which will be held at 3:00 p.m., local time, on August 25, 2025, at
July 18, 2025	CORRESP	SciSparc Ltd. 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel SciSparc Ltd. 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel July 18, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: SciSparc Ltd. (CIK 0001611746) Registration Statement No. 333-282351 on Form F-4 (the “Registration Statement”) Ladies and Gentlemen: SciSparc Ltd. (the “Registrant”) hereby requests acceler
July 8, 2025	CORRESP	* * * July 8, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
July 8, 2025	F-4/A	As filed with the Securities and Exchange Commission on July 8, 2025 As filed with the Securities and Exchange Commission on July 8, 2025 Registration No.
July 8, 2025	EX-99.1	THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. Exhibit 99.1 SCISPARC LTD. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel. VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time, August 24, 2025. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an el
July 7, 2025	LETTER	LETTER July 7, 2025 Oz Adler Chief Executive Officer SciSparc Ltd. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel Re: SciSparc Ltd. Amendment No. 8 to Registration Statement on Form F-4 Filed June 25, 2025 File No. 333-282351 Dear Oz Adler: We have reviewed your amended registration statement and have the following comment(s). Please respond to this letter by amending your registration statem
June 26, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 (Report No. 4) Commission file nu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 (Report No. 4) Commission file number: 001- 38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of
June 26, 2025	EX-99.1	THE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF SCISPARC LTD. As Adopted on June 26, 2025 Exhibit 99.1 THE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF SCISPARC LTD. As Adopted on June 26, 2025 Preliminary 1. Definitions; Interpretation. (a) In these Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite them, respectively, unless the subject or context requires otherwise. “Affiliate” with
June 26, 2025	EX-99.2	COMPENSATION POLICY SCISPARC LTD. Compensation Policy for Executive Officers and Directors (As Adopted on June 26, 2025) Exhibit 99.2 COMPENSATION POLICY SCISPARC LTD. Compensation Policy for Executive Officers and Directors (As Adopted on June 26, 2025) A. Overview and Objectives 1. Introduction This document sets forth the Compensation Policy for Executive Officers and Directors (this “Compensation Policy” or “Policy”) of SciSparc Ltd. (“SciSparc” or the “Company”), in accordance with the requirements of the Compa
June 25, 2025	EX-FILING FEES	Calculation of Filing Fee Tables Form F-4 (Form Type) SciSparc Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Tables Form F-4 (Form Type) SciSparc Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Security Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Sec
June 25, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June (Report No.3) Commission file number: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June (Report No.3) Commission file number: 001- 38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of prin
June 25, 2025	EX-99.1	THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. Exhibit 99.1 SCISPARC LTD. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel. VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time, August 12, 2025. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an el
June 25, 2025	F-4/A	As filed with the Securities and Exchange Commission on June 25, 2025 As filed with the Securities and Exchange Commission on June 25, 2025 Registration No.
June 24, 2025	EX-99.1	Following the reverse share split, the Company will have approximately 534,600 outstanding shares, out of which approximately 516,727 will be publicly held Exhibit 99.1 SciSparc Announces 1-for-21 Reverse Share Split Following the reverse share split, the Company will have approximately 534,600 outstanding shares, out of which approximately 516,727 will be publicly held Tel Aviv, Israel, June 24, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the develo
June 24, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 (Report No. 2) Commission file nu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of
June 18, 2025	F-3/A	As filed with the Securities and Exchange Commission on June 18, 2025 As filed with the Securities and Exchange Commission on June 18, 2025 Registration No.
June 18, 2025	CORRESP	* * * June 18, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
June 12, 2025	LETTER	LETTER June 12, 2025 Oz Adler Chief Executive Officer SciSparc Ltd. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel Re: SciSparc Ltd. Amendment No. 1 Registration Statement on Form F-3 Filed June 10, 2025 File No. 333-286099 Dear Oz Adler: We have reviewed your amended registration statement and have the following comment(s). Please respond to this letter by amending your registration statemen
June 11, 2025	CORRESP	SciSparc Ltd. 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel SciSparc Ltd. 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel June 11, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: SciSparc Ltd. (CIK 0001611746) (the “Company”) Registration Statement No. 333-286099 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our letter, filed a
June 10, 2025	EX-99.1	THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. Exhibit 99.1 SCISPARC LTD. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel. VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time, August 5, 2025. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an ele
June 10, 2025	EX-FILING FEES	Calculation of Filing Fee Tables Form F-4 (Form Type) SciSparc Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Tables Form F-4 (Form Type) SciSparc Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Security Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Sec
June 10, 2025	F-4/A	As filed with the Securities and Exchange Commission on June 9, 2025 As filed with the Securities and Exchange Commission on June 9, 2025 Registration No.
June 10, 2025	CORRESP	SciSparc Ltd. 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel SciSparc Ltd. 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel June 10, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: SciSparc Ltd. (CIK 0001611746) Registration Statement No. 333-286099 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: SciSparc Ltd. (the “Registrant”) hereby requests acceler
June 10, 2025	F-3/A	As filed with the Securities and Exchange Commission on June 10, 2025 As filed with the Securities and Exchange Commission on June 10, 2025 Registration No.
June 9, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 Commission file number: 001-38041 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal execu
June 9, 2025	EX-99.2	AutoMax Motors Ltd. Consolidated Financial Statements for December 31, 2024 AutoMax Motors Ltd. Consolidated Financial Statements for December 31, 2024 Table of Contents Exhibit 99.2 AutoMax Motors Ltd. Consolidated Financial Statements for December 31, 2024 AutoMax Motors Ltd. Consolidated Financial Statements for December 31, 2024 Table of Contents Page Auditor’s report to the shareholders F-2 - F-3 Consolidated statements of financial position F-4 - F-5 Consolidated statements of profit and loss F-6 Consolidated statements of comprehensive income F-7 Consolidat
June 9, 2025	EX-99.1	UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION As previously disclosed, on April 10, 2024, SciSparc Ltd., or the Parent Company or SciSparc entered into an Agreement and Plan of Merger with AutoMax Motors Ltd., an Israeli company traded on the Tel Aviv Stock Exchange and the leading parallel importer and distributor of vehicles in Israel, or AutoMax, and SciSparc Merger
June 9, 2025	EX-99.3	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 99.3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements of SciSparc Ltd (“SciSparc”) on Form F-3 (File No. 333-286099, File No. 333-275305, File No. 333-269839, File No. 333-266047, File No. 333-255408 and File No. and 333-248670) and in the Registration Statements of SciSparc on Form S-8 (File No. 333
May 27, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2025 (Report No. 3) Commission file num UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2025 (Report No. 3) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of p
May 27, 2025	EX-99.1	THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. Exhibit 99.1 SCISPARC LTD. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel. VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time, , 2025. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic
May 27, 2025	EX-99.1	SciSparc Announces Publication of Japanese Patent Application Exhibit 99.1 SciSparc Announces Publication of Japanese Patent Application TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the publication of a Japanese divisional pat
May 27, 2025	CORRESP	* * * May 27, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
May 27, 2025	F-4/A	As filed with the Securities and Exchange Commission on May 27, 2025 As filed with the Securities and Exchange Commission on May 27, 2025 Registration No.
May 23, 2025	LETTER	LETTER May 23, 2025 Oz Adler Chief Executive Officer SciSparc Ltd. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel Re: SciSparc Ltd. Amendment No. 5 to Registration Statement on Form F-4 Filed May 14, 2025 File No. 333-282351 Dear Oz Adler: We have reviewed your amended registration statement and have the following comment(s). Please respond to this letter by amending your registration stateme
May 21, 2025	EX-99.2	THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. Exhibit 99.2 SCISPARC LTD. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel. VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time, June 24, 2025. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an elec
May 21, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of: May 2025 (Report No. 2) Commission file nu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of: May 2025 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916, Israel (Address of
May 21, 2025	EX-99.1	Notice of Annual General Meeting of Shareholders To be Held on June 25, 2025 Exhibit 99.1 May 21, 2025 Dear SciSparc Ltd. Shareholders: We cordially invite you to attend the Annual General Meeting of Shareholders of SciSparc Ltd. (the “Meeting”), to be held on Wednesday, June 25, 2025 at 3:00 p.m. (Israel time), at the Company’s offices, at 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel. At the Meeting, shareholders will be asked to consider and vote on the ma
May 14, 2025	EX-10.5	AMENDMENT No. 3 TO LOAN AGREEMENT Exhibit 10.5 AMENDMENT No. 3 TO LOAN AGREEMENT This Amendment (the “Amendment”) to that certain Loan Agreement dated January 14, 2024, as amended by Amendment No. 1 dated June 9, 2024 and Amendment No. 2 dated September 5, 2024 (“Amendment No. 2”) (together, the “Loan Agreement”), by and between SciSparc Ltd., an Israeli limited company (the “Lender”), and AutoMax Motors Ltd., an Israeli limited c
May 14, 2025	F-4/A	As filed with the Securities and Exchange Commission on May 14, 2025 As filed with the Securities and Exchange Commission on May 14, 2025 Registration No.
May 14, 2025	CORRESP	* * * May 14, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
May 13, 2025	EX-99.1	SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction EX-99.1 2 ea024170802ex99-1scisparc.htm PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC-CLEARMIND COLLABORATION LEADS TO PUBLICATION OF EUROPEAN PATENT FOR PSYCHEDELIC-BASED COMBINATION THERAPY FOR COCAINE ADDICTION." Exhibit 99.1 SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction AVIV, Israel, May 12, 202
May 13, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2025 Commission file number: 001-38041 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2025 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal execut
May 9, 2025	LETTER	LETTER May 9, 2025 Oz Adler Chief Executive Officer SciSparc Ltd. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel Re: SciSparc Ltd. Amendment No. 4 to Registration Statement on Form F-4 Filed April 29, 2025 File No. 333-282351 Dear Oz Adler: We have reviewed your amended registration statement and have the following comment(s). Please respond to this letter by amending your registration statem
April 29, 2025	F-4/A	As filed with the Securities and Exchange Commission on April 28, 2025 As filed with the Securities and Exchange Commission on April 28, 2025 Registration No.
April 28, 2025	EX-FILING FEES	CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) SCISPARC LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) SCISPARC LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee SciSparc Ltd. 2023 Share Incen
April 28, 2025	S-8	As filed with the Securities and Exchange Commission on April 28, 2025 As filed with the Securities and Exchange Commission on April 28, 2025 Registration No.
April 28, 2025	CORRESP	* * * April 28, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
April 25, 2025	EX-99.1	SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders Exhibit 99.1 SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the centr
April 25, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 (Report No. 2) Commission file n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of
April 24, 2025	EX-4.26	addendum no. 3 to AGREEMENT AND PLAN OF MERGER Exhibit 4.25 addendum no. 3 to AGREEMENT AND PLAN OF MERGER This addendum, dated March 27, 2025 (the “Effective Date”) constitutes addendum no. 3 (the “Addendum”) to that certain Agreement and Plan Of Merger dated April 10, 2024, as amended by Addendum No. 1 dated August 14, 2024, and Addendum No. 2 dated November 26, 2024 (hereinafter together, the “Agreement”), by and between, SciSparc Ltd., an
April 24, 2025	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.
April 24, 2025	EX-12.1	CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a) I, Oz Adler, certify that: 1. I have reviewed this annual report on Form 20–F of SciSparc Ltd. (the “Company”); 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances unde
April 24, 2025	EX-15.1	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 Kost Forer Gabbay & Kasierer 144 Menachem Begin Road, Building A Tel-Aviv 6492102, Israel Tel: +972-3-6232525 Fax: +972-3-5622555 ey.com CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statements (Form F-3 Nos. 333-269839, 333-266047, 333-248670, and 333-255408) of SciSparc
April 24, 2025	EX-2.1	DESCRIPTION OF SHARE CAPITAL Exhibit 2.1 DESCRIPTION OF SHARE CAPITAL The following description of SciSparc Ltd.’s (the “Company”) share capital and provisions of the amended and restated articles of association (the “Articles”) are summaries and do not purport to be complete. Registration number and purposes of the Company Our registration number with the Israeli Registrar of Companies is 51-358165-2. Our purpose as set fort
April 24, 2025	EX-13.1	CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by SpiSparc Ltd. (the “Company”), the undersigned, as the Chief Executive Officer and Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report ful
April 24, 2025	EX-11.1	SCISPARC LTD. INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN COMPANY SECURITIES Date: April 23, 2025 Exhibit 11.1 SCISPARC LTD. INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN COMPANY SECURITIES Date: April 23, 2025 This Insider Trading Policy (the “Policy”) provides guidelines to directors, officers, employees and other related individuals of SciSparc Ltd., an Israeli company (the “Company”), with respect to transactions in the Company’s securities. The Company has
April 2, 2025	LETTER	LETTER April 2, 2025 Oz Adler Chief Executive Officer SciSparc Ltd. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel Re: SciSparc Ltd. Registration Statement on Form F-3 Filed March 25, 2025 File No. 333-286099 Dear Oz Adler: We have conducted a limited review of your registration statement and have the following comment(s). Please respond to this letter by amending your registration statement
April 1, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 (Report No. 1) Commission file n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 (Report No. 1) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of
April 1, 2025	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 (Report No. 1) Commission file n Filed by SciSparc Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: AutoMax Motors Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 (Report No. 1) Commission file number: 001-38041 SCISPAR
April 1, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 (Report No. 2) Commission file n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of
March 25, 2025	LETTER	LETTER March 25, 2025 Oz Adler Chief Executive Officer SciSparc Ltd. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel Re: SciSparc Ltd. Amendment No. 3 to Registration Statement on Form F-4 Filed March 11, 2025 File No. 333-282351 Dear Oz Adler: We have reviewed your amended registration statement and have the following comment(s). Please respond to this letter by amending your registration sta
March 25, 2025	EX-FILING FEES	Calculation of Filing Fee Table Form F-3 (Form Type) SciSparc Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) SciSparc Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, no par value 457(
March 25, 2025	F-3	As filed with the Securities and Exchange Commission on March 25, 2025 As filed with the Securities and Exchange Commission on March 25, 2025 Registration No.
March 11, 2025	EX-99.1	SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea Exhibit 99.1 SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea TEL AVIV, Israel, March 10, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central ner
March 11, 2025	F-4/A	As filed with the Securities and Exchange Commission on March 10, 2025 As filed with the Securities and Exchange Commission on March 10, 2025 Registration No.
March 11, 2025	EX-10.8	Loan Agreement Exhibit 10.8 Loan Agreement This Loan Agreement (the “Agreement”) is made on February 24, 2025 (the “Effective Date”) by and between, SciSparc Ltd., an Israeli limited company (the “Lender”) and AutoMax Motors Ltd., an Israeli limited company (the “Borrower”). WHEREAS, the Lender is willing to extend a loan to the Borrower, under the terms and conditions set forth herein. NOW, THEREFORE, the parti
March 11, 2025	EX-99.1	THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. Exhibit 99.1 SCISPARC LTD. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel. VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time, , 2025. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic
March 11, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 (Report No. 2) Commission File N UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 (Report No. 2) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of
March 10, 2025	CORRESP	* * * March 10, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
March 4, 2025	LETTER	LETTER March 4, 2025 Oz Adler Chief Executive Officer SciSparc Ltd. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel Re: SciSparc Ltd. Amendment No. 2 to Registration Statement on Form F-4 Filed February 13, 2025 File No. 333-282351 Dear Oz Adler: We have reviewed your amended registration statement and have the following comment(s). Please respond to this letter by amending your registration s
March 3, 2025	EX-10.1	SECURITIES PURCHASE AND EXCHANGE AGREEMENT Exhibit 10.1 Execution Version SECURITIES PURCHASE AND EXCHANGE AGREEMENT This SECURITIES PURCHASE AND EXCHANGE AGREEMENT (the “Agreement”) is entered into as of February 25, 2025 by and among N2OFF, Inc., a Nevada corporation, with an office address of HaPardes 134 (Meshek Sander), Neve Yarak, Israel (“N2OFF” or the “Purchaser”), MitoCareX Bio Ltd., a private company incorporated under the laws o
March 3, 2025	EX-10.1	SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers SciSparc will sell its MitoCareX’s shares for $700,000 and exchange its remaining shares for common stock in N2OFF Exhibit 99.1 SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers SciSparc will sell its MitoCareX’s shares for $700,000 and exchange its remaining shares for common stock in N2OFF TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutica
March 3, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-3804 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal exec
February 27, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 (Report No. 3) Commission Fil UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 (Report No. 3) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
February 27, 2025	EX-99.1	1 Exhibit 99.1 SciSparc Extends $2 Million Loan to Support AutoMax’s Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles TEL AVIV, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, anno
February 27, 2025	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 (Report No. 3) Commission Fil Filed by SciSparc Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: AutoMax Motors Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 (Report No. 3) Commission File Number: 001-38041 SCIS
February 27, 2025	EX-4.2	ORDINARY SHARES PURCHASE WARRANT SCISPARC LTD. Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T
February 27, 2025	EX-4.1	SCISPARC LTD. Convertible Debenture Exhibit 4.1 NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXC
February 27, 2025	EX-10.5	Loan Agreement Exhibit 10.5 Loan Agreement This Loan Agreement (the “Agreement”) is made on February 24, 2025 (the “Effective Date”) by and between, SciSparc Ltd., an Israeli limited company (the “Lender”) and AutoMax Motors Ltd., an Israeli limited company (the “Borrower”). WHEREAS, the Lender is willing to extend a loan to the Borrower, under the terms and conditions set forth herein. NOW, THEREFORE, the parti
February 27, 2025	EX-10.3	GLOBAL GUARANTY AGREEMENT Exhibit 10.3 GLOBAL GUARANTY AGREEMENT This Guaranty is made as of February 25, 2025 by BRAIN BRIGHT LTD., (“Brain Bright”) and EVERO HEALTH LTD., (“Evero Health” and collectively with Brain Bright, the “Guarantors”) in favor of YA II PN, LTD. (the “Creditor”), with respect to all obligations of SCISPARC LTD., a company incorporated under the laws of the State of Israel (the “Debtor”) owed to the
February 27, 2025	EX-10.2	SECURITIES PURCHASE AGREEMENT Exhibit 10.2 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of February 25, 2025, is between SCISPARC LTD., a company incorporated under the laws of the State of Israel, with principal executive offices located at 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (the “Company”), and each of the investors listed on the Schedule of Buyers att
February 27, 2025	EX-10.4	REGISTRATION RIGHTS AGREEMENT Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 25, 2025, is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and SCISPARC LTD., a company incorporated under the laws of the State of Israel (the “Company”). The Investor and the Company may be referred to herein individually as a “Par
February 27, 2025	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of February 24, 2025, is between SCISPARC LTD., a company incorporated under the laws of the State of Israel, with principal executive offices located at 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (the “Company”), and each of the investors listed on the Schedule of Buyers att
February 18, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 (Report No. 2) Commission Fil UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 (Report No. 2) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
February 18, 2025	EX-99.1	SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology Exhibit 99.1 SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development
February 13, 2025	F-4/A	As filed with the Securities and Exchange Commission on February 13, 2025 As filed with the Securities and Exchange Commission on February 13, 2025 Registration No.
February 13, 2025	EX-10.6	DISTRIBUTION AGREEMENT By and Between ANHUI JIANGHUAI AUTOMOBILE GROUP CORP., LTD. AUTOMAX LEASING COMPANY AUTOMAX LEASING Ref. NO. _____________ Sep 15th, 2024, Hefei CHINA Exhibit 10.6 Certain identified information contained in this document, marked by brackets, was omitted because it is both (i) not material and (ii) is the type that the Company treats as private or confidential. “[***]” indicates where the information has been omitted from this exhibit. DISTRIBUTION AGREEMENT By and Between ANHUI JIANGHUAI AUTOMOBILE GROUP CORP., LTD. And AUTOMAX LEASING COMPANY
February 13, 2025	EX-10.7	TRANSLATED FROM HEBREW FOR CONVENIENCE PURPOSES ONLY Founders’ Agreement That was made and signed in Tel Aviv on June 16, 2022 Exhibit 10.7 Certain identified information contained in this document, marked by brackets, was omitted because it is both (i) not material and (ii) is the type that the Company treats as private or confidential. “[***]” indicates where the information has been omitted from this exhibit. TRANSLATED FROM HEBREW FOR CONVENIENCE PURPOSES ONLY Founders’ Agreement That was made and signed in Tel Aviv o
February 13, 2025	CORRESP	* * * February 13, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
February 4, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal e
February 4, 2025	EX-99.1	SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico Exhibit 99.1 SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico TEL AVIV, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, annou
January 27, 2025	LETTER	LETTER January 27, 2025 Oz Adler Chief Executive Officer SciSparc Ltd. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel Re: SciSparc Ltd. Amendment No. 1 to Registration Statement on Form F-4 Filed December 31, 2024 File No. 333-282351 Dear Oz Adler: We have reviewed your amended registration statement and have the following comment(s). Please respond to this letter by amending your registratio
January 21, 2025	POS AM	As filed with the Securities and Exchange Commission on January 21, 2025 As filed with the Securities and Exchange Commission on January 21, 2025 Registration No.
January 15, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 2) Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
January 15, 2025	EX-99.1	No Immediate Effect on Nasdaq Listing or Trading of the Company’s Ordinary Shares Exhibit 99.1 SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement No Immediate Effect on Nasdaq Listing or Trading of the Company’s Ordinary Shares TEL AVIV, Israel, Jan. 15, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat dis
January 7, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number: 001-38 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal ex
January 7, 2025	EX-99.1	SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment Exhibit 99.1 SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment TEL AVIV, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central ner
December 31, 2024	EX-99.1	SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder Exhibit 99.1 SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system,
December 31, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 3) Commission Fil UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 3) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
December 31, 2024	EX-2.4	addendum no. 2 to AGREEMENT AND PLAN OF MERGER Exhibit 2.4 addendum no. 2 to AGREEMENT AND PLAN OF MERGER This addendum, dated November 26, 2024 (the “Effective Date”) constitutes addendum no. 2 (the “Addendum”) to that certain Agreement and Plan Of Merger dated April 10, 2024, as amended by Addendum No. 1 dated August 14, 2024 (hereinafter together, the “Agreement”), by and between, SciSparc Ltd., an Israeli limited company (the “Parent”), Sc
December 31, 2024	EX-10.6	DISTRIBUTION AGREEMENT By and Between ANHUI JIANGHUAI AUTOMOBILE GROUP CORP., LTD. AUTOMAX LEASING COMPANY AUTOMAX LEASING Ref. NO. _____________ Sep 15th, 2024, Hefei CHINA Exhibit 10.6 Certain confidential information contained in this document, marked by brackets, was omitted because it is both (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed. “[***]” indicates where the information has been omitted from this exhibit. DISTRIBUTION AGREEMENT By and Between ANHUI JIANGHUAI AUTOMOBILE GROUP CORP., LTD. And AUTOMAX LEAS
December 31, 2024	EX-10.7	TRANSLATED FROM HEBREW FOR CONVENIENCE PURPOSES ONLY Founders’ Agreement That was made and signed in Tel Aviv on June 16, 2022 Exhibit 10.7 Certain confidential information contained in this document, marked by brackets, was omitted because it is both (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed. “[***]” indicates where the information has been omitted from this exhibit. TRANSLATED FROM HEBREW FOR CONVENIENCE PURPOSES ONLY Founders’ Agreement That was made and signed i
December 31, 2024	CORRESP	* * * December 31, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
December 31, 2024	F-4/A	As filed with the Securities and Exchange Commission on December 31, 2024 As filed with the Securities and Exchange Commission on December 31, 2024 Registration No.
December 26, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 2) Commission fil 6-K 1 ea0226065-6kscisparc.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 R
December 26, 2024	EX-99.1	SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation Exhibit 99.1 SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation TEL AVIV, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distributor in Israel with which the Company has entered into an agreemen
December 26, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 2) Commission fil Filed by SciSparc Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: AutoMax Motors Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 2) Commission file number: 001-38041 SCIS
December 17, 2024	EX-99.1	SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company According to the LOI, SciSparc’s pharmaceuticals assets are valued at approximately US$11.6 million Exhibit 99.1 SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company According to the LOI, SciSparc’s pharmaceuticals assets are valued at approximately US$11.6 million TEL AVIV, Israel, Dec. 16, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical compa
December 17, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal e
November 29, 2024	EX-99.2	AutoMax Motors Ltd. Summary of Interim Consolidated Financial Information June 30, 2024 AutoMax Motors Ltd. Consolidated Financial Statements June 30, 2024 Table of Contents Exhibit 99.2 AutoMax Motors Ltd. Summary of Interim Consolidated Financial Information June 30, 2024 (Unaudited) AutoMax Motors Ltd. Consolidated Financial Statements June 30, 2024 Table of Contents Page Auditor’s review report for shareholders Summary of statements on the consolidated interim financial condition F-2 - F-3 Summary of consolidated interim profit and loss reports F-4 Summary of cons
November 29, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 3) Commission fil UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 3) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
November 29, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 3) Commission fil Filed by SciSparc Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: AutoMax Motors Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 3) Commission file number: 001-38041 SCIS
November 29, 2024	EX-99.1	UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION As previously disclosed, on April 10, 2024, SciSparc Ltd., or the Parent Company or SciSparc entered into an Agreement and Plan of Merger with AutoMax Motors Ltd., an Israeli company traded on the TASE and the leading parallel importer and distributor of vehicles in Israel, or AutoMax, and SciSparc Merger Sub Ltd., an Israel
November 27, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 2) Commission fil Filed by SciSparc Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: AutoMax Motors Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 2) Commission file number: 001-38041 SCIS
November 27, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 2) Commission fil UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
November 4, 2024	EX-99.2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjuncti
November 4, 2024	EX-99.1	SCISPARC LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 Exhibit 99.1 SCISPARC LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 UNAUDITED INDEX Page Consolidated Statements of Financial Position 2-3 Consolidated Statements of Profit or Loss and Other Comprehensive Loss 4 Consolidated Statements of Changes in Equity (Deficit) 5-7 Consolidated Statements of Cash Flows 8-10 Notes to Interim Consolidated Financial Statements 11-23 SCISPARC
November 4, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 Commission file number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal e
October 23, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2024 (Report No. 2) Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2024 (Report No. 2) Commission file number: 001- 38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
October 23, 2024	LETTER	LETTER October 23, 2024 Oz Adler Chief Executive Officer SciSparc Ltd. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel Re: SciSparc Ltd. Registration Statement on Form F-4 Filed September 26, 2024 File No. 333-282351 Dear Oz Adler: We have reviewed your registration statement and have the following comment(s). Please respond to this letter by amending your registration statement and providing
October 22, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2024 (Report No. 1) Commission file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2024 (Report No. 1) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address
September 27, 2024	EX-99.1	Supplemental Proxy Statement Annual General Meeting of Shareholders to be held on October 22, 2024 Exhibit 99.1 September 27, 2024 Supplemental Proxy Statement Annual General Meeting of Shareholders to be held on October 22, 2024 This supplemental proxy statement (the “Supplemental Proxy Statement”) is being furnished in connection with the solicitation of proxies on behalf of the board of directors (the “Board”), of SciSparc Ltd. (“SciSparc” or the “Company”) to be voted at the Annual General
September 27, 2024	EX-99.2	THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. Exhibit 99.2 SCISPARC LTD. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel. VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time, Monday, October 21, 2024. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to cre
September 27, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of: September 2024 (Report No. 6) Commission f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of: September 2024 (Report No. 6) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916, Israel (Addre
September 26, 2024	F-4	As filed with the Securities and Exchange Commission on September 26, 2024 As filed with the Securities and Exchange Commission on September 26, 2024 Registration No.
September 26, 2024	EX-99.3	CONSENT TO BE NAMED AS DIRECTOR Exhibit 99.3 CONSENT TO BE NAMED AS DIRECTOR In connection with the Registration Statement on Form F-4 (including any and all amendments, including post-effective amendments, or supplements thereto, the “Registration Statement”) of SciSparc Ltd. (the “Company”), the undersigned hereby consents to being named and described in the Registration Statement filed with the U.S. Securities and Exchange Co
September 26, 2024	EX-4.1	PREFUNDED ORDINARY SHARE PURCHASE WARRANT SCISPARC LTD. Exhibit 4.1 PREFUNDED ORDINARY SHARE PURCHASE WARRANT SCISPARC LTD. Warrant Shares: Date of Issuance: , 2024(“Issuance Date”) This PREFUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the issuance of the Merger Consideration (as defined in the Merger Agreement (as defined below), [HOLDER] (including any permitted and registered assigns, t
September 26, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2024 (Report No. 5) Commission fi UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2024 (Report No. 5) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Addres
September 26, 2024	EX-99.1	SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX Exhibit 99.1 SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX The intended selling valuation represents an increase of 47% from the valuation at the time of SciSparc’s initial investment in MitoCareX Bio TEL AVIV, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on
September 26, 2024	EX-99.4	CONSENT TO BE NAMED AS DIRECTOR Exhibit 99.4 CONSENT TO BE NAMED AS DIRECTOR In connection with the Registration Statement on Form F-4 (including any and all amendments, including post-effective amendments, or supplements thereto, the “Registration Statement”) of SciSparc Ltd. (the “Company”), the undersigned hereby consents to being named and described in the Registration Statement filed with the U.S. Securities and Exchange Co
September 26, 2024	EX-99.2	WRITTEN CONSENT OF E.D.B. CONSULTING AND INVESTMENTS LTD July 16 2024 Exhibit 99.2 WRITTEN CONSENT OF E.D.B. CONSULTING AND INVESTMENTS LTD July 16 2024 The Board of Directors SciSparc Ltd. 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel To the Board of Directors of SciSparc Ltd. We refer to the valuation report of our firm, dated January 9, 2024 (the “Valuation Report”), included in the proxy statement/prospectus on Form F-4 (the “Registration Statement
September 26, 2024	EX-FILING FEES	Calculation of Filing Fee Tables Form F-4 (Form Type) SciSparc Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Tables Form F-4 (Form Type) SciSparc Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Security Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Sec
September 26, 2024	EX-10.4	AMENDMENT No. 2 TO LOAN AGREEMENT Exhibit 10.4 AMENDMENT No. 2 TO LOAN AGREEMENT This Amendment (the “Amendment”) to that certain Loan Agreement dated January 14, 2024, as amended by Amendment dated June 9, 2024 (together, the “Loan Agreement”), by and between SciSparc Ltd., an Israeli limited Company (the “Lender”), and AutoMax Motors Ltd., an Israeli limited company (the “Borrower”), is entered into effect as of September 5, 202
September 26, 2024	EX-10.3	AMENDMENT TO LOAN AGREEMENT Exhibit 10.3 AMENDMENT TO LOAN AGREEMENT This Amendment (the “Amendment”) to that certain Loan Agreement (“Loan Agreement”) dated January 14, 2024 (the “Effective Date”), by and between SciSparc Ltd., an Israeli limited Company (the “Lender”), and AutoMax Motors Ltd., an Israeli limited company (the “Borrower”), is entered into effect as of June 9, 2024 (the “Amendment Effective Date”). Unless oth
September 26, 2024	EX-2.3	addendum no. 1 to AGREEMENT AND PLAN OF MERGER Exhibit 2.3 addendum no. 1 to AGREEMENT AND PLAN OF MERGER This addendum, dated August 14, 2024 (the “Effective Date”) constitutes addendum no. 1 (the “Addendum”) to that certain Agreement and Plan Of Merger dated April 10, 2024 (hereinafter together, the “Agreement”), by and between, SciSparc Ltd., an Israeli limited company (the “Parent”), SciSparc Merger Sub Ltd., an Israeli limited company and
September 26, 2024	EX-10.5	FORM OF indemnification agreement Exhibit 10.5 FORM OF indemnification agreement THIS INDEMNIFICATION AGREEMENT (the “Agreement”), dated as of , 2024, is entered into by and between SciSparc Ltd., an Israeli company whose address is 20 Raul Wallenberg St., Tower A, 2nd Floor, Tel Aviv 6971916, Israel (the “Company”), and the undersigned Director or Officer of the Company whose name appears on the signature page hereto officer (the
September 26, 2024	EX-10.2	Loan Agreement Exhibit 10.2 Loan Agreement This Loan Agreement (the “Agreement”) is made on January 14, 2024 (the “Effective Date”) by and between, SciSparc Ltd., an Israeli limited company (the “Lender”) and AutoMax Motors Ltd., an Israeli limited company (the “Borrower”). WHEREAS, the Borrower and the Lender intend to enter into a merger agreement, upon consummation of which the Borrower will become a wholly o
September 23, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2024 (Report No. 4) Commission fi UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2024 (Report No. 4) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Addres
September 23, 2024	EX-99.1	SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment FDA confirms that SciSparc’s study may proceed following the application submission a month ago Exhibit 99.1 SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment FDA confirms that SciSparc’s study may proceed following the application submission a month ago TEL AVIV, Israel, Sept. 23, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of th
September 16, 2024	EX-99.1	SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy This innovative drug combination treatment focuses on boosting safety and efficacy in mental health Exhibit 99.1 SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and addiction care TEL AVIV, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a special
September 16, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2024 (Report No. 3) Commission fi UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2024 (Report No. 3) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Addres
September 11, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2024 (Report No. 2) Commission fi Filed by SciSparc Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: AutoMax Motors Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2024 (Report No. 2) Commission file number: 001-38041 SCI

SPRC / SciSparc Ltd. - SEC-Einreichungen, Jahresbericht, Proxy Statement

Basisstatistiken

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?